JAK-IN-5

CAS No. 2096999-92-5

JAK-IN-5( —— )

Catalog No. M26263 CAS No. 2096999-92-5

JAK-IN-5 is a JAK inhibitor (Compound 283 from patent US20170121327A1).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 371 Get Quote
10MG 552 Get Quote
25MG 879 Get Quote
50MG 1188 Get Quote
100MG 1602 Get Quote
500MG 3204 Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    JAK-IN-5
  • Note
    Research use only, not for human use.
  • Brief Description
    JAK-IN-5 is a JAK inhibitor (Compound 283 from patent US20170121327A1).
  • Description
    JAK-IN-5 is a JAK inhibitor (Compound 283 from patent US20170121327A1).
  • In Vitro
    ——
  • In Vivo
    JAK-IN-5 (compound 1) (oral aspirate, 0.5 mg/mL, 50 μL ) inhibits STAT6 phosphorylation by 60% in IL-13-induced in lung tissue in a mouse model of pSTAT6 induction.JAK-IN-5 (compound 1) (oral aspirate, 0.1-1.0 mg/mL, 50 μL) inhibits 88% of BALF eosinophils in male C57 mice model of Alternaria alternata-induced eosinophilic inflammation of the lung.
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    JAK
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2096999-92-5
  • Formula Weight
    474.584
  • Molecular Formula
    C27H31FN6O
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    CCc1cc(O)c(F)cc1-c1ccc2c(n[nH]c2c1)-c1nc2CN(CCc2[nH]1)C1CCN(C)CC1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Zhao H, Liu Q et al. In vitro additive antitumor effects of dimethoxycurcumin and 5-fluorouracil in colon cancer cells. Cancer Med. 2017 Jul;6(7):1698-1706.
molnova catalog
related products
  • Tofacitinib citrate

    A potent, specific, orally active inhibitor of JAK3 with IC50 of 1 nM in cell-free assays; displays 20- to 100-fold less potency for JAK2 and JAK1 (IC50=20 nM and 112 nM, respectively).

  • NVP-BSK805

    A potent, selective and ATP-competitive inhibitor of JAK2(V617F) and wt JAK2 (IC50=0.5 nM).

  • Atiprimod dihydrochl...

    Atiprimod (SKF 106615, Azaspirane) is a potent, orally bioavailable JAK2 inhibitor, inhibits phosphorylation of JAK2 and the downstream STAT3 and STAT5 pathways.